Why the study?
The study aimed to evaluate the effect of dapagliflozin on the no-reflow phenomenon in patients with type II diabetes mellitus and acute myocardial infarction undergoing percutaneous coronary intervention.
Does dapagliflozin reduce the no-reflow phenomenon in patients with T2DM and AMI undergoing PCI?
Does dapagliflozin reduce the no-reflow phenomenon in patients with T2DM and AMI undergoing PCI?
Prior long-term use of dapagliflozin is associated with a reduced incidence of the angiographic no-reflow phenomenon in patients with T2DM undergoing PCI for acute myocardial infarction.
Should not yet change practice for no-reflow prevention; leaves open need for RCTs to confirm association.
OBJECTIVE: This study aimed to assess the effect of dapagliflozin on the no-reflow phenomenon in patients with type II diabetes mellitus (T2DM) and acute myocardial infarction (AMI) who underwent percutaneous coronary intervention (PCI). METHODS: This single-center, observational cohort study included a total of 829 consecutive T2DM patients who were diagnosed with AMI and underwent PCI within 24 h of the onset of symptoms. Only patients using dapagliflozin (10 mg per day) for more than one year were considered as patients using dapagliflozin. The no-reflow phenomenon was defined as inadequate myocardial perfusion within a segment of the coronary circulation without angiographic evidence of mechanical vessel obstruction, dissection, or residual stenosis after PCI. CONCLUSION: Lower rates of the no-reflow phenomenon were observed in T2DM patients taking dapagliflozin, diagnosed with AMI, and underwent PCI. However, this finding requires further investigation.
No takes yet. Share an insight, caveat, or question.
Quisi et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: